SARS-CoV-2 刺突蛋白：疫苗的最佳免疫靶标。
SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
机构信息
Takis s.r.l, Via di Castel Romano 100, 00128, Rome, Italy.
Evvivax s.r.l, Via di Castel Romano, 100, 00128, Rome, Italy.
出版信息
J Transl Med. 2020 Jun 3;18(1):222. doi: 10.1186/s12967-020-02392-y.
Abstract
COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effective therapeutics. Here, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus has been the Spike protein, considered as the ideal target for COVID-19 immunotherapies.
摘要
COVID-19 已迅速在全球蔓延，演变成大流行。这种情况紧急促使许多公司和公共研究机构集中精力研究有效的治疗方法。在这里，我们概述了目前开发针对 SARS-CoV-2 疫苗所采用的策略和靶标。基于以前对 SARS 和 MERS 的证据和经验，主要关注点是 Spike 蛋白，它被认为是 COVID-19 免疫疗法的理想靶标。
相似文献
1
SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.SARS-CoV-2 刺突蛋白：疫苗的最佳免疫靶标。
J Transl Med. 2020 Jun 3;18(1):222. doi: 10.1186/s12967-020-02392-y.
2
mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.信使核糖核酸疫苗：对抗严重急性呼吸综合征冠状病毒2的潜在工具
Virol Sin. 2020 Jun;35(3):259-262. doi: 10.1007/s12250-020-00243-0. Epub 2020 Jun 10.
3
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.一种新型的基于受体结合域（RBD）的抗SARS-CoV-2 mRNA疫苗。
Cell Res. 2020 Oct;30(10):932-935. doi: 10.1038/s41422-020-0387-5. Epub 2020 Aug 5.
4
Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.SARS-CoV-2 刺突蛋白的前景：在疫苗和治疗开发中的潜在作用。
Virus Res. 2020 Oct 15;288:198141. doi: 10.1016/j.virusres.2020.198141. Epub 2020 Aug 23.
5
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.一种针对严重急性呼吸综合征冠状病毒 2 刺突蛋白 RBD 的疫苗可诱导保护性免疫。
Nature. 2020 Oct;586(7830):572-577. doi: 10.1038/s41586-020-2599-8. Epub 2020 Jul 29.
6
Coronavirus vaccines get a biotech boost.冠状病毒疫苗获得生物技术助力。
Nature. 2020 Jul;583(7817):647-649. doi: 10.1038/d41586-020-02154-2.
7
Rapid COVID-19 vaccine development.新冠疫苗的快速研发。
Science. 2020 May 29;368(6494):945-946. doi: 10.1126/science.abb8923. Epub 2020 May 8.
8
Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.自扩增 RNA SARS-CoV-2 脂质纳米颗粒疫苗候选物在小鼠中诱导高中和抗体滴度。
Nat Commun. 2020 Jul 9;11(1):3523. doi: 10.1038/s41467-020-17409-9.
9
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.CEPI/BC 2020 年 3 月 12-13 日会议共识总结报告：评估 COVID-19 疫苗引起疾病增强的风险。
Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25.
10
Fast-and-fit vaccines.快速适配疫苗
Nat Biomed Eng. 2020 Aug;4(8):757-758. doi: 10.1038/s41551-020-00605-9.
引用本文的文献
1
Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection.不断演变的新冠病毒疫苗：从当前解决方案到广谱保护
Vaccines (Basel). 2025 Jun 12;13(6):635. doi: 10.3390/vaccines13060635.
2
Discovery of Antibodies Against Endemic Coronaviruses with NGS-Based Human Fab Phage Display Platform.基于二代测序的人源Fab噬菌体展示平台发现针对地方性冠状病毒的抗体
Antibodies (Basel). 2025 Mar 27;14(2):28. doi: 10.3390/antib14020028.
3
Dynamics of spike-specific neutralizing antibodies across five-year emerging SARS-CoV-2 variants of concern reveal conserved epitopes that protect against severe COVID-19.五年间新冠病毒变异株中刺突蛋白特异性中和抗体的动态变化揭示了可预防重症新冠的保守表位。
Front Immunol. 2025 Feb 18;16:1503954. doi: 10.3389/fimmu.2025.1503954. eCollection 2025.
4
Antibody-dependent enhancement of coronaviruses.冠状病毒的抗体依赖性增强作用。
Int J Biol Sci. 2025 Feb 3;21(4):1686-1704. doi: 10.7150/ijbs.96112. eCollection 2025.
5
Screening of Natural Compounds as Inhibitor of M SARS-CoV-2 Protein; A Molecular Dynamics Approach.筛选天然化合物作为新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）蛋白的抑制剂；一种分子动力学方法。
Curr Pharm Des. 2025;31(7):559-574. doi: 10.2174/0113816128315762240828052002.
6
Dynamics of Spike-Specific Neutralizing Antibodies Across Five-Year Emerging SARS-CoV-2 Variants of Concern Reveal Conserved Epitopes that Protect Against Severe COVID-19.跨越五年的新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）关注变异株中刺突蛋白特异性中和抗体的动态变化揭示了可预防重症冠状病毒病2019（COVID-19）的保守表位
bioRxiv. 2024 Sep 25:2024.09.22.614369. doi: 10.1101/2024.09.22.614369.
7
Optimization and validation of a virus-like particle pseudotyped virus neutralization assay for SARS-CoV-2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒样颗粒假型化病毒中和试验的优化与验证
MedComm (2020). 2024 Jun 14;5(6):e615. doi: 10.1002/mco2.615. eCollection 2024 Jun.
8
Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases.用于通过接种疫苗、未接种疫苗和突破性感染 SARS-CoV-2 的病例建立血清学特征的多重中尺度发现免疫原性检测的验证和适用性评估
Vaccines (Basel). 2024 Apr 18;12(4):433. doi: 10.3390/vaccines12040433.
9
Quantitative Assessment of Energetic Contributions of Residues in a SARS-CoV-2 Viral Enzyme/Nanobody Interface.定量评估 SARS-CoV-2 病毒酶/纳米抗体界面残基的能量贡献。
J Chem Inf Model. 2024 Mar 25;64(6):2068-2076. doi: 10.1021/acs.jcim.3c01933. Epub 2024 Mar 9.
10
Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development.SARS-CoV-2 刺突蛋白的免疫表位及通用疫苗开发的考虑因素。
Immunohorizons. 2024 Mar 1;8(3):214-226. doi: 10.4049/immunohorizons.2400003.
本文引用的文献
1
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.鉴定 2019 新型冠状病毒的受体结合域（RBD）：作为病毒附着抑制剂和疫苗开发 RBD 蛋白的意义。
Cell Mol Immunol. 2020 Jun;17(6):613-620. doi: 10.1038/s41423-020-0400-4. Epub 2020 Mar 19.
2
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.严重急性呼吸系统综合征冠状病毒 2 刺突糖蛋白的结构、功能和抗原性。
Cell. 2020 Apr 16;181(2):281-292.e6. doi: 10.1016/j.cell.2020.02.058. Epub 2020 Mar 9.
3
Is COVID-19 receiving ADE from other coronaviruses?新冠病毒是否会从其他冠状病毒中获得增强效应？
Microbes Infect. 2020 Mar;22(2):72-73. doi: 10.1016/j.micinf.2020.02.006. Epub 2020 Feb 22.
4
Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine.用灭活SARS-CoV疫苗免疫的恒河猴中SARS-CoV感染的抗体依赖性增强作用的评估
Virol Sin. 2018 Apr;33(2):201-204. doi: 10.1007/s12250-018-0009-2. Epub 2018 Mar 14.
5
Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.一种强效人源单克隆抗体对中东呼吸综合征冠状病毒的预防及暴露后疗效
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8. doi: 10.1073/pnas.1510199112. Epub 2015 Jul 27.
6
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.抗体依赖性 SARS 冠状病毒感染是由针对刺突蛋白的抗体介导的。
Biochem Biophys Res Commun. 2014 Aug 22;451(2):208-14. doi: 10.1016/j.bbrc.2014.07.090. Epub 2014 Jul 26.
7
Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus.严重急性呼吸综合征冠状病毒通过抗体依赖性感染人巨噬细胞。
Virol J. 2014 May 6;11:82. doi: 10.1186/1743-422X-11-82.
8
Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.接种 SARS 冠状病毒疫苗会导致在 SARS 病毒攻击时肺部免疫病理学发生。
PLoS One. 2012;7(4):e35421. doi: 10.1371/journal.pone.0035421. Epub 2012 Apr 20.
9
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.一种从记忆B细胞制备人单克隆抗体的有效方法：对严重急性呼吸综合征冠状病毒的有效中和作用
Nat Med. 2004 Aug;10(8):871-5. doi: 10.1038/nm1080. Epub 2004 Jul 11.
10
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.严重急性呼吸综合征冠状病毒结构蛋白对保护性免疫的贡献。
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9. doi: 10.1073/pnas.0403492101. Epub 2004 Jun 21.
Zotero 插件